Home > News & Media > News
Communication starts here.
2014.12
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China
2014.12
TWi Biotechnology receives approval of protocol for its drug AC-201 Controlled-Release Tablet, Phase II clinical trial in both the United States and Taiwan
2014.10
TWi Pharmaceuticals Receives US FDA Approval on Generic Donepezil Hydrochloride Tablets USP, 23 mg, its fifth ANDA from US FDA
2014.10
TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 in United States.
2014.08
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension
2014.06
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States.
2014.06
Twi Pharmaceuticals, Inc. announces the acquisition of Hainan Visum Pharmaceutical Co., Ltd in China, starting the new chapter of international mergers and acquisitions.
2014.04
TWi Announces Settlement of Lidoderm® Patent Litigation
2014.04
TWi Announces ANDA Approval of Generic Procardia XL® Tablets 30 mg, 60 mg and 90mg in the United States
2014.02
TWi Pharmaceuticals Confirms Favorable Ruling in Generic MEGACE ES® Patent Suit

 

Pages:1 - 2 - 3 - 4 - 5 - 6 - 7 - 8« Pre · Next »